	US 11,814,430 B2
	Increasing responses to checkpoint inhibitors by extracorporeal apheresis
Thomas Emanuel Ichim, San Diego, CA (US); Steven Francis Josephs, San Diego, CA (US); Stephen Michael Prince, San Diego, CA (US); Amir Jafri, San Diego, CA (US); Robert Segal, San Dieog, CA (US); and David L. Schlotterbeck, San Diego, CA (US)
Assigned to IMMUNICOM, INC., San Diego, CA (US)
Filed by IMMUNICOM, INC., San Diego, CA (US)
Filed on Feb. 12, 2021, as Appl. No. 17/175,503.
Application 17/175,503 is a continuation of application No. PCT/US2019/031184, filed on May 7, 2019.
Prior Publication US 2021/0163597 A1, Jun. 3, 2021
Int. Cl. C07K 16/28 (2006.01); A61M 1/34 (2006.01); A61M 1/36 (2006.01)

CPC C07K 16/2818 (2013.01) [A61M 1/3496 (2013.01); A61M 1/3693 (2013.01); C07K 16/2827 (2013.01); A61M 2202/0415 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01)]

11 Claims

1. A method of treating or ameliorating the effects of a tumor in a patient with non-small cell lung cancer (NSCLC) comprising:

identifying a patient having a tumor;

selecting an antibody selected from the group consisting of: an anti-PD-1 antibody and an anti-PD-L1 antibody;

administering said antibody to said patient to treat or ameliorate the effects of said tumor; and

extracorporeally removing soluble Tumor Necrosis Factor (TNF)-alpha receptor from said patient.